CMV-Free Porcine Donor Selection for Xenotransplant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current xenotransplant procedures face challenges in achieving extended survival of transplanted tissues and organs due to immunogenicity issues, particularly with the presence of porcine cytomegalovirus (pCMV) in donor swine, leading to reduced graft survival and increased rejection rates.
Innovation Solution
The method involves selecting CMV-free porcine donors by performing PCR or RT-PCR assays to detect latent or active pCMV, and using these donors for xenotransplant procedures, including skin grafts, to minimize immunogenicity and enhance graft survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If xenotransplant tissues are obtained from standard porcine sources, then the procedure is simpler and more readily available, but the transplant survival is reduced and rejection rates increase due to immunogenicity issues
Solution Approach 1:
The patent applies preliminary action by performing PCR-based screening assays on candidate donor swine to detect latent or active pCMV infections before selecting donors for xenotransplantation. This advance detection and selection process identifies CMV-free donors, ensuring that transplants from these selected donors achieve extended survival without accelerated rejection. The screening is performed prior to transplant procurement, allowing only negative candidates to be chosen as donors.
2Duration of action of moving object
If PCR screening is performed on all candidate donors, then rejection rates are reduced and graft survival is extended, but the time and resources required for donor evaluation increase
Solution Approach 1:
The patent extracts and specifically targets the pCMV viral genetic material from candidate donor swine using PCR-based assays. By focusing the screening on detecting only pCMV DNA or RNA sequences rather than performing comprehensive health evaluations, the method efficiently identifies CMV-free donors. This targeted extraction approach minimizes screening time and resources while ensuring that selected donors lack pCMV infection, thereby enabling extended graft survival.
3Object-affected harmful factors
If CMV-free donors are selected through rigorous screening, then immunogenicity is reduced and transplant survival is extended, but the complexity of the selection process increases
Solution Approach 1:
The patent replaces complex serological or cultural methods with PCR-based molecular detection to identify pCMV in candidate donors. The PCR assay specifically amplifies pCMV genetic sequences from blood or tissue samples, providing a highly sensitive and specific detection method. This molecular approach substitutes simpler but less accurate mechanical or visual inspection methods, enabling reliable identification of CMV-free donors and reduction of immunogenicity in xenotransplants.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in extended transplant survival and reduced rejection rates, allowing for longer-term temporary coverage of injuries such as burns until allogeneic or autologous grafts can be obtained, with the potential for serial grafting without accelerated rejection.
Implementation Method 1
performing an assay (e.g., a PCR or RT-PCR based assay) on the sample to detect the presence of latent or active porcine cytomegalovirus (pCMV) in the sample
Data Source
AI summary
Methods of preparing and porcine cells, organs and tissues that have reduced immunogenicity, e.g., for transplant into humans, e.g., for the treatment of burn injuries.